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Abstract
Epidemiologic studies have documented that the majority of women do not become depressed during
the menopause transition. However, recent longitudinal studies suggest that in some women, the
events related to the menopause transition could play a role in the onset of depression. In this article
we review evidence suggesting a relationship between the menopause transition and depression.
Additionally, we describe several findings that suggest a role of ovarian hormones in the onset of
these depressions, including the clustering of episodes of depression during the stage of the
menopause transition that is accompanied by estradiol withdrawal, and the therapeutic effects of
short-term estradiol in depressed perimenopausal women. Finally, we discuss possible causes of
affective disturbances during the menopause transition.
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The focus of this article is the potential relationship between the onset of affective disorders
in women and the reproductive events of the menopause transition. First, we will present
background information relevant to the controversy surrounding the putative relationship
between reproductive aging and affective disorders, review the endocrinology of this phase of
a woman’s life, and describe those methodologic problems that have hindered efforts to clarify
the existence and nature of a potential relationship between the onset of depression and the
menopause transition. Second, we will describe studies examining the prevalence and
presentation of mood disorders occurring during the menopause transition. We will also
emphasize several emerging methodologic issues that may help resolve otherwise discrepant
findings between previous epidemiologic studies and those published more recently. Third, we
will review evidence from basic studies that both demonstrate the manifold regulatory actions
of ovarian steroids on central nervous system (CNS) function and provide biologically
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plausible mechanisms that could underly the relationship between the reproductive events
during the menopause transition and the onset of affective disorders. Finally, we will discuss
possible causes of affective dysregulation during the menopause transition.
HISTORICAL PERSPECTIVES
The nineteenth-century medical literature contains numerous case reports and medical
commentaries describing mood and behavioral disorders in women during midlife and
reproductive aging. In his 1899 Textbook of Mental Disease, Bevan Lewis1 described the
clinical presentations of women with climacteric-related mood disorders as follows:
Pre-eminently is this the case at the menopause and grand climacteric, when the whole
of this system loses its functional activity, degenerates, and, in fact, passes almost
completely out of the life of the individual. Both subjective and objective
accompaniments of the menstrual molimen in a greatly-exaggerated degree
emphasise and usher-in this serious disturbance of the nervous-centres—headache,
vertigo, faintness, “heat flushes,” emotional waves, phases of moral perversity,
irritability, querulous impatience, even intellectual disturbance (especially of memory
and of attention) prevail; and, wanting the relief afforded by the depurative process
of menstruation, the distress is often a long-continued and urgent one. This, however,
is the earlier stage of functional decrepitude, the early phase of which is characterised
by want of decision, lassitude, and hebetude. It is essentially a period of voluminous
emotions, purposeless waves of feeling, abortive yearnings, redundant, vague,
uncontrolled desires, and misdirected energy. That great reservoir of nerve-force,
which had for its object the procreative functions of the organism, is now
objectiveless, and its expenditure must now be directed into other channels; a period
of emotional instability ushers in a period of reconstructions.
These early observations, in turn, led to speculations about the role of ovarian steroids in brain
function and psychiatric illness, speculations supported by the anecdotal reports of the
psychotropic actions of ovarian extracts. Nonetheless, in the psychiatric literature, a debate
ensued regarding the nature of these mood and behavioral disturbances and their connection
to reproductive aging. Descriptions of involutional- and climacteric-related syndromes in the
nineteenth century ranged from minor depressive illnesses (neurasthenia-like) to more severe
forms of depressive illness with psychotic features. For example, Conklin2 described a
syndrome reminiscent of minor depression or a mixed anxiety-depressive state occurring in
the context of vasomotor symptoms and numerous somatic symptoms, whereas Maudsley3
reported a more classical endogenomorphic depression, in association with delusions of guilt
and episodes of psychomotor agitation. The depression described by Maudsley in England was
also described in Germany by both Kraepelin4 and Bleuler.5 Although Kraepelin’s description
of involutional melancholia was not confined to women, the described clinical presentation
resembled Maudsley’s climacteric melancholia. Based on the clinical presentations (e.g., late
onset, absence of mania), involutional melancholia was excluded from manic-depressive
psychosis and considered a separate entity with a variable prognosis. The separateness of this
syndrome was postulated on the basis of differences in symptomatology, age of onset of index
episode, premorbid personality, and family history. Subsequently, Stenstedt6 further
distinguished menopause-related involutional patients from other types of involutional
depression by observing the former group to exhibit less severe symptoms and lower risk for
affective disorder in family members. The controversy surrounding these conditions was not
whether a menopausal mood syndrome existed, but how it should be classified.
Despite the debate over classification, a mood disorder called involutional psychotic reaction
appeared in the first Diagnostic and Statistical Manual of Mental Disorders (DSM).7 The
association between involutional depression and ovarian aging was supported further following
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the successful isolation and synthesis of ovarian steroids. The widespread use of estrogen
therapy in the 1940s led to reports of the therapeutic benefits of estrogen therapy in women
with involutional melancholia.8 Thus, mainstream psychiatry (albeit not without dissent)9
accepted the existence of a type of mood disorder related to reproductive aging—and, in fact,
inferred a causal association between the two events, given both the timing of onset and
preliminary suggestions of the beneficial effects of estrogen therapy.
Prior to DSM-III, several more systematic studies investigated the nature of the relationship
between the reproductive aging and the onset of mood disorders in women. In particular, studies
by Weissman10 and Winokur11 were unable to confirm the existence of involutional
melancholia or to identify epidemiologic evidence for an increased prevalence of major
depressive disorder during the menopause. Thus, the earlier debate over the appropriate
classification of involutional melancholia changed to skepticism about its existence as a distinct
condition. Moreover, these findings suggested that hormonal events did not underlie mood
disorders occurring during midlife and reproductive aging.
In summary, several studies10-12 provided evidence against the validity of the involutional
melancholia construct in that (1) there appeared to be no distinct symptom pattern, (2) there
was no distinct pattern of previous episodes of depression in patients with menopause-related
major depressive episodes, (3) there was no increased risk for suicide or psychiatric
hospitalization during the menopause, and (4) there appeared to be no increased prevalence of
depression during the menopause. Additionally, despite a generally higher prevalence rate of
depression in females compared to males, some studies12 reported a slightly lower six-month
prevalence rate of depression during the presumed menopausal/climacteric years than in
younger age groups.
This evidence, however, was far from conclusive in refuting the existence of a menopause-
related mood syndrome. Despite similar or lower point prevalence rates and similar clinical
presentations of depression during the menopause and at other times of life, one cannot infer
that these syndromes share identical etiologies. For example, both Stenstedt6 and Brown and
colleagues13 reported involutional-onset depression to be associated with a lower family
history of depression than that observed in patients with early-onset depression. Thus, although
major depressions that occur during the menopause do not appear phenomenologically distinct
from earlier-onset depressions, evidence suggests that the two may differ with respect to family
history and the age of the index depressive episode.
The presupposition that menopause-related affective syndromes, if they exist, are forms of
melancholic depression is an additional confound that may have interfered with the
identification and characterization of other affective syndromes (e.g., minor depression)
occurring at or around the menopause. Many of the original reports described a clinical picture
during the menopause that was more consistent with a neurasthenia or minor depression. For
example, Winokur11 observed that the symptoms of depression and anxiety were so common
during the menopause that an additional criterion for depression (i.e., hospitalization) was
imposed for the older (but not the younger) depressed women, thus spuriously decreasing the
rate of observed affective disorders in the years surrounding the menopause. Given Winokur’s
observation of the high frequency of reports of menopause-related affective symptomatology
in this group, it seems unwarranted for him to have concluded that there is “little value in
looking specifically at the menopausal state for clues to the etiology of ordinary affective
disorder.”
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REPRODUCTIVE ENDOCRINOLOGY OF THE MENOPAUSE TRANSITION
AND THE POSTMENOPAUSE
The menopause is defined as the permanent cessation of menstruation resulting from loss of
ovarian activity. It is characterized endocrinologically by tonically elevated gonadotropin
(follicle stimulating hormone [FSH], luteinizing hormone [LH]) secretion, persistently low
levels of ovarian steroids (estradiol, progesterone), and relatively low (50% decrease compared
to younger age groups) androgen secretion.14 The menopause transition and perimenopause
are defined as the transitional periods from reproductive to nonreproductive life.15 The average
duration of the menopause transition (defined by menstrual cycle irregularity) is estimated to
be approximately 4 years, but there is considerable individual variation in the duration of this
phase of reproductive life, ranging from 0 to 11 years.16,17 During the early stages of
reproductive aging, the follicular phase of the menstrual cycle shortens,18,19 early follicular
phase plasma FSH levels increase, and plasma inhibin B levels decrease.20-22 As the
menopause transition progresses, ovarian follicular depletion occurs, the ovary becomes less
sensitive to gonadotropin stimulation, and a state of relative hypoestrogenism occurs;
gonadotropin secretion is elevated across the menstrual cycle; ovulatory cycles are fewer; and
menstrual cycle irregularity ensues. In contrast to the postmenopause, however, episodic (not
tonic) gonadotropin secretion is present, and both ovulation and normal premenopausal (or at
times, increased) estradiol secretion may occur.15,23-25 The late menopause transition is
characterized endocrinologically by persistent elevations of plasma FSH, sustained menstrual
cycle irregularity with periods of amenorrhea, and hypoestrogenism. Also decreasing with
aging, concomitant with changes in reproductive function, are the levels of several other
hormones that may affect mood and behavior—including androgens (testosterone and
androstenedione), which begin to decline in the 20s and reach peak decline during the late 40s
and 50s, dehydroepiandrosterone (DHEA), and insulin-like growth factors and binding
proteins.23,26-29
Not only is there evidence suggesting the importance of distinguishing between peri- and
postmenopausal women with respect to treatment response characteristics (see below), but
studies also have identified that the perimenopause has distinct endocrine characteristics, with
the early menopause transition (e.g., high gonadotropin levels and possibly increased estradiol
secretion) differing from the late menopause transition (e.g., high gonadotropin levels, estradiol
withdrawal, and initial onset of sustained hypogonadism). Thus, investigators have attempted
to develop criteria to define the phases of reproductive aging more carefully and thereby to
facilitate a more precise understanding of the interaction between the stage of ovarian failure,
aging, and a variety of physiological events. For example, the Stages of Reproductive Aging
Workshop (STRAW) criteria for reproductive, perimenopausal (menopausal transition), and
postmenopausal years developed by Soules and colleagues14 define the early menopause
transition (stage −2) to include women with menstrual cycle irregularity (defined as a variable
cycle length that differs from normal by more than 7 days) and elevated plasma FSH secretion,
whereas during the late menopause transition (stage −1), there is a continued elevation of FSH
in conjunction with two or more skipped cycles and a period of amenorrhea lasting at least 60
days. The perimenopause includes both stages −2 and −1, as well as up to one year of
amenorrhea after which the woman has entered the early postmenopause.
PAST METHODOLOGIC PROBLEMS AND EMERGING CONCEPTS IN
INVESTIGATIONS OF THE RELATIONSHIP BETWEEN MOOD DISORDERS
AND REPRODUCTIVE AGING
Methodologic problems in previous studies related to the manner in which both reproductive
status and mood syndromes were defined have compromised researchers’ ability to understand
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the role of reproductive aging in mood disorders and the role of estradiol in treating these
disorders.
Characterizing Reproductive Status
Several criteria have been employed to define the reproductive status of women participating
in studies of the relationship between menopause and mood. One criterion is to use an age
window of 45 to 55 years to select perimenopausal subjects. Although the average age of the
menopause is 51 years, there is considerable individual variation in the age of onset of the
menopause, ranging from the early 40s to the late 50s. Adopting an age window as the sole
selection criteria will inevitably result in the selection of a heterogenous sample of women,
with some premenopausal, some perimenopausal, and some postmenopausal. Under a second
criterion, age is combined with retrospective or prospective self-reports of menstrual cycle
disturbance; the menopause is defined as six months to one year of amenorrhea, and the
perimenopause as menstrual cycle irregularity. Self-reports of menstrual cycle irregularity,
however, cannot be used to reliably define reproductive status. Treloar16 observed that
menstrual cycle irregularity is not confined to the perimenopause and may occur frequently
during other periods of reproductive life. In a sample of women at midlife, Kaufert and
colleagues30 observed that during a three-year period of follow-up, as many women reporting
menstrual cycle irregularity returned to normal menstrual cycle function as entered the
menopause (defined by six months of amenorrhea). Moreover, there is a 5%–10% probability
that a woman could have menstrual bleeding even after 12 months of amenorrhea.31 Finally,
recent studies suggest that either persistent cycle lengths of >40 days or periods of amenorrhea
of >60 days are more predictive of the onset of the menopause within one to two years than
the less specific criteria of either isolated episodes of elongated cycles or skipped menses.32,
33 Thus, previous studies relying on self-reports of menstrual cycle irregularity also would be
at risk for selecting samples of women at different stages of reproductive aging. A third criterion
commonly used to define reproductive status is the presence of elevated plasma FSH levels.
Perimenopause-related elevations in gonadotropins may be reversible, however, and in our
sample of 310 women who had four serial FSH levels drawn every two weeks for six weeks,
an elevated FSH (>20 IU/L) during the first sampling was not subsequently confirmed in 10%
of cases (Khine et al., unpublished data). Indeed, a recent study confirmed that an elevated
plasma FSH level is an independent marker of the late menopause transition; however, FSH
levels alone were less predictive of menopausal stage than bleeding patterns.34 A combination
of age, menstrual cycle history, and plasma gonadotropin levels may be the most reliable
method for selecting and characterizing the reproductive status of perimenopausal women, but
it will not be predictive of future reproductive function in every woman.
Defining Mood Syndromes
Another methodological problem is the failure to define midlife mood disorder as a syndrome
—as a condition meeting standardized diagnostic criteria; what is seen, instead, is only an
unintegrated set of symptoms. Mood symptoms differ from mood syndromes, however, in their
instruments of detection, their duration, and their impact. Structured interviews introduce
criteria similar to those present in DSM-IV35 to ensure diagnostic homogeneity within samples
and comparability across studies. For example, in addition to the presence of the DSM-IV core
symptom criteria, the Structured Clinical Interview for DSM-IV (SCID-IV)36 specifies that
symptoms of depression must be present nearly every day for most of the day and persist for
at least two weeks. The SCID also requires that the severity of depression be rated from mild
to severe based on the number of symptoms in excess of those required for the diagnosis of
minor or major depression and the level of functional impairment. In contrast, the cross-
sectional scales employed in many community-based surveys measure the severity of
depressive-like symptoms but do not assess either the longitudinal persistence of a core group
of depressive symptoms or the level of functional impairment, both important constituents of
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a depressive syndrome. Additionally, cross-sectional rating scales, such as the Center for
Epidemiological Studies–Depression (CES-D), have restricted sampling intervals consisting
of a one- to two-week window of time prior to the date when the scale is completed. Thus, if
50% of major depressive episodes remit within three months, as reported previously,37 then
the administration of a cross-sectional rating on a yearly basis, for example, could not reliably
assess the occurrence of depression during the previous year.38
In addition employing standardized psychiatric diagnostic interviews to establish the presence
of current and past psychiatric mood syndromes, investigators need to define and identify the
type of mood syndromes that they are investigating. For example, both major and minor
depressions exist, yet many studies focus only on the presence of major depression, with the
exclusion of minor depression justified on the basis of its lesser significance. During the
puerperium, however, the incidence of minor depression is comparable to that of major
depression.39
MOOD DISORDERS OCCURRING DURING REPRODUCTIVE AGING IN
WOMEN
The majority of women do not develop depression during the menopause transition or after the
menopause. In fact, epidemiologic studies examining gender- and age-related differences in
the six-month to one-year prevalence of major depression reported no increased prevalence of
major depression in women at midlife (age range approximately 45–55 years).40,41 Similarly,
others have concluded that the onset of the menopause is not associated with an increased risk
for developing depression;42-51 however, in four studies,44,45,49,50 symptoms were observed
more frequently in perimenopausal than postmenopausal women. Indeed, in several other
longitudinal, community-based studies, the perimenopause (or the presence of menstrual cycle
irregularity and hot flushes) was associated with an increased risk for depression,52-57
consistent with studies of women attending gynecology clinics.58-60 The Study of Women’s
Health Across the Nation (SWAN)54 employed a measure of “psychological distress” as a
proxy for the syndrome of depression by requiring that core depressive symptoms (sadness,
anxiety, and irritability) persist for at least two weeks (similar to the duration criterion
employed in DSM-IV). SWAN’s initial cross-sectional survey observed that perimenopausal
women reported significantly more “psychological distress” than either pre- or postmenopausal
women (defined by self-reported menstrual cycle status).54 The results of several studies
published during the last three years have found similar results. First, in a longitudinal study,
Freeman and colleagues57 found an increased risk for clinically significant depression (defined
by elevated CES-D scale scores and the Primary Care Evaluation of Mental Disorders)61 during
the perimenopause compared to the pre- or postmenopause. This association remained after
adjusting for several variables, including past history of depression, severe premenstrual
syndrome, poor sleep, and hot flushes. Levels of depression were increased relative to those
found in postmenopausal women; however, only 3% of the sample (approximately ten of the
women in the study) was followed through to the postmenopause. In a second prospective
study, Cohen and colleagues62 evaluated the risk of depression in 460 women who were
followed prospectively for up to seven years and who had no past history of depression. The
risk of new-onset depression (defined by the SCID-IV) in the perimenopause was nearly twice
that observed in the premenopause (adjusted OR = 1.8). Third, in a similar study to that of
Cohen and colleagues,62 Freeman and colleagues63 demonstrated a significantly increased (2½
times greater) rate of new-onset depression in women with no history of depression during the
late perimenopause compared to women with no history of depression who remained
premenopausal. Finally, two recent reports by Bromberger and colleagues64,65 demonstrate an
increased incidence of first-onset and recurrent major and minor depressive episodes during
the late menopause transition and early postmenopause. These data notwithstanding, the
majority of women in these studies remained asymptomatic throughout the perimenopause.
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These data suggest, however, that events occurring during the menopause transition and early
postmenopause may predispose some women to develop clinically significant depressive
illness.
The stage of the menopause transition during which episodes of depression appear could
provide clues to the physiologic events accompanying the onset of depression. We have
examined the temporal linkage between the stages of the menopause transition and depression
in two studies. First, we prospectively examined asymptomatic premenopausal women with
regular menstrual cycles to determine if the onsets of depression clustered during a specific
stage of the menopause transition. Women were followed with behavioral and reproductive
measures for an average of five years until six months to one year after the last menstrual
period. In a preliminary report of 29 women, we documented nine episodes of major or minor
depression in 8 women, only 2 of whom had a prior depressive episode. A 14-fold increase in
the rate of onset of depression was observed during the 24 months surrounding the final
menstrual period, relative to the 31 years used as a comparison time period. These data
document a clustering of depressive episodes in women during the late menopause transition
relative to the premenopause.66 Second, we performed a cross-sectional study of 116 women
presenting to the National Institute of Mental Health midlife clinic for evaluation and treatment
—all of whom met criteria for perimenopause-onset major or minor depression. The majority
of depressive episodes occurred during STRAW stage 1 (the late menopause transition),
regardless of the presence of vasomotor symptoms or a past history of depression.67 The stage
of the menopause transition (i.e., late stage) during which depressive episodes appear supports
a pathophysiologic role of endocrine events since the late perimenopause is characterized by
estradiol “withdrawal” relative to either the postmenopause or the early perimenopause.15,23
Thus, the temporal appearance of the depressions observed suggests an endocrine trigger
related to the perimenopause (estradiol withdrawal or recent onset of prolonged hypogonadism)
in the onset of perimenopausal depression.
Anxiety Symptoms and Syndromes
There also is evidence that clinically significant symptoms of anxiety are experienced by a
considerable number of women during the menopause transition60 and that the frequency of
episodes may increase during the perimenopause.68-71 Freeman and colleagues71 measured
anxiety symptoms with the Zung Inventory in a group of women followed prospectively
through the menopause transition until the final menstrual period. Significant associations
between the severity of anxiety symptoms and the occurrence, severity, and frequency of hot
flushes were identified in these women. Women with the highest anxiety scores (i.e., Zung
Inventory scores > 48) were five times more likely to report hot flushes compared to the non-
anxious perimenopausal women. An increase in the severity of anxiety symptoms during the
menopause transition predicted the occurrence of hot flushes 8 to 12 months later. These
significant associations remained after adjusting for smoking, body mass index (BMI), race,
and depressive symptoms. Thus, the increased autonomic activity and arousal associated with
anxiety could increase a woman’s vulnerability for experiencing hot flushes or could
exaggerate their distressing symptoms. Alternatively, the symptoms of anxiety disorders and
of hot flushes may overlap such that scores on an anxiety measure may be increased in women
who have hot flushes. These data also emphasize that in addition to mood disorders, anxiety
could play a prominent role in the psychological and somatic distress experienced by some
perimenopausal women.
Anxiety syndromes may also occur during the menopause transition. New-onset panic disorder
in the perimenopause was observed anecdotally (Schmidt et al., unpublished observation) and
may be responsive to estrogen therapy; in our experience, however, the frequent comorbidity
of perimenopausal panic disorder with hot flushes and their shared symptomatology prevent
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one from readily separating the two phenomena. Thus, although estradiol treatment may be
effective for panic attacks, it is unclear if this improvement is secondary to relief of hot flushes
(which may trigger as well as mimic panic attacks) or due to the direct effects of estradiol on
panic disorder. Moreover, both hot flushes and panic improve after treatment with selective
serotonin reuptake inhibitors, suggesting potentially shared pathophysiology and also
treatment response characteristics.
Emerging Concepts
These recent studies56,57,62-67 of the relationship between reproductive aging and mood
disturbance have employed more reliable methods for both establishing the presence or absence
of mood syndromes (e.g., structured diagnostic interviews) and characterizing reproductive
status (e.g., STRAW criteria).14 Thus, several new methodologic issues have been identified
that may predict a differential response to changes in hormones (either endogenous or
exogenous), including phase of reproductive aging (i.e., late perimenopause or early
menopause versus five years past last menses), presence of menopausal symptoms, the duration
of hypogonadism prior to receiving hormone therapy, and genetic polymorphisms that underlie
differences in steroid responsivity. A differential response to estradiol in depression was
reported by Appleby,72 with perimenopausal, but not postmenopausal, women responding to
estrogen therapy under randomized, placebo controlled conditions (observations confirmed by
several recent randomized, controlled trials [described below] employing standardized
psychiatric diagnostic interviews to establish the presence of depression).73-75 Similarly, a
literature review and meta-analysis by Yaffe and colleagues76 concluded that the benefits of
hormone therapy on cognitive function were limited to perimenopausal women compared to
postmenopausal women and suggested that the beneficial effects of hormone therapy were
secondary to the concurrent improvement in menopausal symptoms. Subsequent meta-
analyses of a similar literature performed by LeBlanc77 and Hogervorst78 confirmed Yaffe’s
suggestion and observed that the presence of symptoms (e.g., hot flushes, sleep disturbance,
or mood disturbance) predicted a beneficial effect of hormone therapy on cognition. Similarly,
studies in both animals and humans suggest that a short duration of hypogonadism prior to
initiation of estrogen therapy is associated with beneficial effects on measures of
cognition79-81 and on atherosclerotic plaque formation.82 These findings are consistent with
the observed differences in treatment response between perimenopausal or recently
menopausal and older postmenopausal women—the former being more likely to be
symptomatic.58,59 Additionally, these findings introduce the concept of the critical window
for the efficacy of estrogen therapy. For example, both non-human primate and, more recently,
human studies have shown that initiation of hormone is associated with cardioprotection when
administered immediately after oophorectomy—but not after 30 months (approximately six
human years) in nonhuman primates or during the early postmenopause in women.82-86 This
critical-window construct was proposed as an explanation for some of the discrepant findings
between the observational studies (many of which included younger, more symptomatic
women) and the recent randomized, controlled trials related to the Women’s Health Initiative,
87,88 which principally included older asymptomatic women.81,89 Finally, independent of stage
of reproductive life or duration of hypogonadism, several studies employing both plasma lipid
levels and cognitive-outcome measures suggest that the effects of sex steroids may be
influenced by the presence of polymorphisms in specific steroid receptors.90,91
In summary, epidemiologic studies examining the prevalence of both affective symptoms and
syndromes have documented that the majority of postmenopausal women do not experience a
major depression associated with this phase of life. Nevertheless, several community-based
and clinic-based surveys suggest that the perimenopause is relevant to the development of
affective disorders and that a substantial number of perimenopausal women do, in fact,
experience a clinically significant affective syndrome.
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NEUROREGULATORY POTENTIAL OF ALTERATIONS IN OVARIAN STEROID
SECRETION
Results from animal and human studies demonstrate that gonadal steroids influence several of
the neuroregulatory systems thought to be involved in both the pathophysiology of affective
disorders and the efficacy of antidepressant therapies.92-94 These findings suggest that under
certain circumstances the changes in ovarian steroids accompanying the menopause transition
could sufficiently alter brain function so as to manifest in affective maladaptation and
depression. Preclinical, pharmacological, postmortem, and in vivo imaging studies implicate
alterations in classical neurotransmission (e.g., increased serotonin transporter function;
decreased cortical 5HT1A receptors) in the etiology and treatment of depression. In some, but
not all,95 experimental paradigms, estradiol, like antidepressants, has been observed to inhibit
serotonin transporter mRNA, protein, and binding;96-98 decrease 5HT1A receptor activity
(down-regulation and uncoupling from its G-protein);99,100 increase 5HT2A binding and
mRNA;101 and facilitate imipramine-induced downregulation of 5HT2 receptors in rat frontal
cortex.102
In addition to classic neurotransmitter systems, several neural-signaling systems have been
identified as potential mediators of the therapeutic actions of antidepressants and
electroconvulsive therapy (ECT) (e.g., cyclic adenosine monophosphate [cAMP] response
element-binding protein [CREB] and brain-derived neurotrophic factor [BDNF])103 based on
observations that these systems are modulated by a range of therapies effective in depression
(e.g., serotonergic and noradrenergic agents and ECT) and that they exhibit patterns of change
consistent with the latency to therapeutic efficacy for most antidepressants.104 For example,
antidepressants increase the expression and activity of CREB in certain brain regions (e.g.,
hippocampus)105 and regulate (in a brain region–specific manner) activity of genes with a
cAMP response element.104 Genes for BDNF and its receptor TrkB have been proposed as
potential targets for antidepressant-related changes in CREB activity,104-106 and recent reports
demonstrate that BDNF levels are increased by treatment with antidepressants107-109
Similarly, estradiol was reported to influence many of these same neuroregulatory processes.
Specifically, in animal models, ovariectomy was reported to decrease, and estradiol increase,
BDNF levels in the forebrain and hippocampus.110-112 In the rat brain, estradiol also increases
CREB activity113 and TrkA,110 and decreases GSK-3 beta activity (Wnt pathway) in a direction
similar to that seen with mood stabilizers. In contrast, an estradiol-induced decrease in BDNF
was reported to mediate estradiol’s regulation of dendritic spine formation in hippocampal
neurons.114 Polymorphisms in genes involved in signal transduction may also influence the
response to treatment.115 For example, polymorphisms in the G-protein beta subunit GNB3
C825T, which results in a 41 amino acid deletion, have been significantly associated with lack
of remission and response to antidepressant treatment.116 Data from animal and human studies
demonstrate the ability of estradiol to regulate G-protein function.117-119 Finally, through
effects on cell-survival proteins (e.g., Bcl-2, BAX) and proliferative signal transduction
pathways (MAPK, Wnt, Akt), both reproductive steroids and antidepressants/mood stabilizers
may influence cell energetics in such a way as to influence synaptic plasticity, a process that
is putatively disturbed in depression. Thus, the therapeutic potential of gonadal steroids in
depression is suggested not only by their widespread actions on classical neurotransmitter
systems, but also by a variety of other relevant neuroregulatory actions shared by both estrogen
and traditional therapies for depression (i.e., antidepressants, mood stabilizers, ECT).
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POSSIBLE CAUSES OF MOOD DISORDERS DURING REPRODUCTIVE
AGING
Ovarian Hormone Withdrawal or Deficiency Theory
Several reports indirectly support a role for abnormalities of reproductive hormones during the
perimenopause in depression: (1) hormone replacement beneficially affects both hot flushes
and mood in hypogonadal women;120-123 (2) lower gonadotropin levels are sometimes
observed in postmenopausal, depressed women compared to asymptomatic comparison
groups;124-127 (3) perimenopausal women with depressive symptoms are reported to have
lower plasma estrone levels128 than nondepressed, perimenopausal women; and (4) an
association has been described between increased plasma FSH levels and depression.129 In
contrast, three studies of perimenopausal and postmenopausal women observed either no
diagnosis-related differences in plasma estradiol and FSH130 or no correlation between plasma
levels of estrogens or androgens and severity of depressive symptoms.131,132
In a study of 21 women with their first episode of depression occurring during the
perimenopause and 21 asymptomatic, perimenopausal controls,133 we were unable to confirm
previous reports of lower basal plasma levels of LH124-127 or estrone128 in perimenopausal
and postmenopausal women with depression. Additionally, no diagnosis-related differences
in basal plasma levels of FSH, estrone, testosterone, or free testosterone were observed. These
data are consistent with those of Barrett-Connor and colleagues131 and Cawood and colleagues,
132 who, as described above, found no correlation between mood symptoms and plasma levels
of these hormones.
In addition to ovarian hormones, age-related differences in the function of several other
physiologic systems are observed in both animals and humans. Some of these differences may
occur coincident with the perimenopause and therefore may potentially contribute to mood
dysregulation at this time. Although postmenopausal women are reported to exhibit increased
stress-induced plasma norepinephrine levels compared to premenopausal women,134 only one
previous study128 reported elevated urinary cortisol levels in perimenopausal women reporting
depressive symptoms compared to asymptomatic controls. No systematic study has been
performed of HPA-axis function in untreated perimenopausal depressed women.
A role for the adrenal androgen DHEA and its sulfated metabolite (DHEA-S) in the regulation
of mood state is suggested by both its effects on neural physiology135,136 and its potential
synthesis within the central nervous system.137 Moreover, in clinical trials, DHEA
administration was reported to improve mood in some,138-141 but not all,142 studies. DHEA’s
potential role in the onset of depression may be particularly relevant at midlife in view of the
declining levels of DHEA production that occur with aging and the accelerated decrease in
DHEA levels reported in women, but not men, during midlife.143 It is therefore possible that
declining secretion (or abnormally low secretion) of DHEA may interact with perimenopause-
related changes in ovarian function to trigger the onset of depression in some women. We133
measured morning plasma levels of DHEA, DHEA-S, and cortisol in a sample of women with
the first onset of depression during the perimenopause and in nondepressed women matched
for age and reproductive status. Depressed perimenopausal women had significantly lower
levels of both plasma DHEA and DHEA-S, but not cortisol, compared to controls.133 These
findings are consistent with several previous studies suggesting an association between DHEA
levels and mood. In one study, plasma DHEA levels correlated with the severity of depressive
symptoms in a group of postmenopausal women, with lower levels of DHEA associated with
higher depression scores.131 In two other studies, a positive correlation between DHEA-S
plasma levels and feelings of well-being was observed in groups of peri- and postmenopausal
women;132 as well as in elderly depressed men and women.144 These differences in DHEA
Harsh et al. Page 10













levels notwithstanding, there was considerable overlap in plasma DHEA levels between
perimenopausal women with and without depression. Thus, at present, in addition to the
limitations of basal hormonal measures, there is not consistent evidence that women who
develop depression during the menopause transition have an ovarian or adrenal hormone
deficiency state.
Perimenopausal depression may not be distinguished from major depressive disorder on the
basis of phenomenology, course, family or personal history of mood disorder, or abnormal
basal levels of ovarian/adrenal steroids. Nonetheless, the relevance of changes in pituitary-
ovarian function to depression during the perimenopause is suggested by two sets of findings:
first, in some depressed, perimenopausal women, mood symptoms improve concurrently with
the restoration of ovarian function;145 and second, estradiol therapy has mood-enhancing
effects in depressed, perimenopausal women.
First, we observed several women who presented to our clinic with depression and whose
plasma FSH levels, obtained at each clinic visit, declined over a 6–8 week period, concurrent
with spontaneous improvements in mood symptoms. We examined whether this putative
relationship between normalization of ovarian function and mood could be generalized. In
particular, we evaluated mood scores and plasma FSH levels serially over a six-week screening
phase in a larger group of women presenting to our clinic with perimenopausal depression. In
the group of women (n = 18) whose CES-D scores decreased by >50%, we observed an
incremental decline in FSH levels at each of the four clinic visits that paralleled the
improvements in CES-D scores.145 Increased plasma FSH levels were not consistently
associated with worsening CES-D scores, and increased CES-D scores were not associated
with corresponding elevations in plasma FSH levels, whereas a more uniform relationship was
observed between mood and plasma FSH level when either measure decreased. Thus, we
identified a subgroup of women with perimenopausal depression whose mood symptoms
remitted spontaneously in association with a significant decline in gonadotropin levels (and a
suggested alteration in pituitary-ovarian function). While not fully convergent with our
observations, in the longitudinal study by Freeman and colleagues,63 mood symptoms were
significantly correlated with both declining plasma estradiol and increasing plasma FSH levels
in those women who entered the late menopause transition and were at the increased risk for
first-onset depression. In contrast to cross-sectional studies that suggest that perimenopausal
depression is not associated with abnormalities of ovarian function, longitudinal studies imply
that there may be a more direct relationship between alterations in pituitary-ovarian function
and mood symptoms in these women.
In the second set of findings, an association between the endocrine events related to the
perimenopause and the onset of depression is also implicated (albeit indirectly) by reports of
the mood enhancing effects of estradiol in depressed, perimenopausal women. Recently, three
double-blind, placebo-controlled trials, which used similar methodologies and identical
preparations of estradiol (i.e., 17 beta estradiol), have examined the efficacy of estradiol in
perimenopausal and postmenopausal women with major or minor depressions.73-75 In the first
of these studies, the therapeutic efficacy of estradiol (17 beta estradiol) was examined in a
double-blind, placebo-controlled trial in 34 perimenopausal women (late perimenopause by
STRAW criteria)14 who also met standardized diagnostic criteria for major and minor
depression.73 After three weeks of estradiol, scores on depression-rating scales were
significantly decreased compared to baseline scores and significantly lower than scores in the
women receiving placebo. A full or partial therapeutic response was seen in 80% of subjects
on estradiol and in 22% of those on placebo, which is consistent with the observed effect size
of 0.7 in a meta-analysis of studies examining estrogen’s effects on mood.146 The therapeutic
response to estrogen was observed in women regardless of the presence of major or minor
depression, a history of non-perimenopause-related depression, or the presence of hot flushes.
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Finally, neither baseline nor posttreatment estradiol levels predicted the observed therapeutic
response. In keeping with recent community-based cross-sectional surveys,54 these data
suggest that estrogen’s effect on depression is not solely a product of its ability to reduce the
distress of hot flushes. These findings also are consistent with data from Montgomery and
colleagues147 and Saletu and colleagues,148 which document the beneficial effects of estradiol
on mood in perimenopausal women reporting depressive symptoms.
A second randomized, double-blind, placebo-controlled study by Soares and colleagues74
confirmed the observations of Schmidt and colleagues.73 In addition to finding a significant,
beneficial effect of estradiol replacement compared to placebo in women with perimenopause-
related major depression (as defined by the Primary Care Evaluation of Mental Disorders),
149 Soares and colleagues74 reported that baseline plasma estradiol levels did not predict
response to estrogen treatment. In contrast, a recent study—one using a design similar to the
ones employed by Schmidt,73 Soares,74 and their colleagues in studying perimenopausal
women73,74—failed to observe a significant antidepressant effect of estradiol relative to
placebo75 in depressed women who were 5–10 years post menopause.
The evidence that younger perimenopausal, but not older postmenopausal, depressed women
respond to estrogen therapy suggests that the mood disorders occurring in perimenopausal
women are caused by changes in hormones (e.g., withdrawal or fluctuations) rather than by
prolonged ovarian steroid deficiency.
Hot Flushes and Dysphoria—The Cascade Theory
A wealth of epidemiologic evidence demonstrates the co-occurrence of both hot flushes and
depression in women during the perimenopause.42,52,57,134,150-152 In a randomized, controlled
trial of 16 hypogonadal (peri- and postmenopausal) women, Schiff and colleagues153 showed
that hot flushes, sleep, and mood all improved after treatment with oral conjugated estrogens.
Based on these findings, a cascade-like effect was suggested in which hot flushes and
perimenopausal depression share a linear, causal relationship between them (i.e., hot flushes
lead to sleep disturbances, which, in turn, lead to dysphoria).
In support of the cascade theory, epidemiologic and clinic-based studies report an increased
frequency of both hot flushes and sleep disorders in aging women during the menopause
transition. Indeed, reports of insomnia have been documented in approximately 45% of
perimenopausal women, with the highest rates of reported insomnia in women during the late
menopause transition.74,154-157 Ohayon158 observed that over 80% of peri- and
postmenopausal women with severe hot flushes also reported a sleep disturbance and that the
severity of hot flushes correlated with the severity and duration of insomnia. Objective
measurements of both sleep and hot flushes have confirmed these associations. Hot flushes
recorded during the first half of the night are associated with frequent awakenings and
subjective sleep disturbance, whereas hot flushes occurring during the second half of the night
have less disruptive effects on sleep, possibly due to a buffering effect of REM sleep (e.g., the
suppression of thermoregulation) on the sleep-disturbing effects of hot flushes.159 Nonetheless,
in a separate study, awakening from sleep as frequently preceded a hot flush as it accompanied
(or followed) one.160 Thus, these latter data do not support a specific linear, causal relationship
between the occurrence of a hot flush and subsequent sleep disturbance.160 Epidemiologic data
also confirm that disturbed sleep is a risk factor for the development of depression,161,162 and
in one clinic-based study, healthy, nondepressed volunteers experienced depressive symptoms
after two days of sleep deprivation.163 Thus, current evidence from both community- and
clinic-based studies provides some, but not uniform, support for a direct, causal relationship
between hot flush–induced sleep disturbances and depression in perimenopausal women.
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Despite the plausibility that hot flushes could sufficiently disturb sleep to result in an increased
risk for depression in perimenopausal women, there is also evidence that challenges this
putative association. First, sleep disturbance can be a symptom of, and not just a risk for,
depression. Similarly, affective symptoms (e.g., anxiety) can precede hot flushes.71 Thus, the
association of these phenomena does not demonstrate causation. Second, polysomnographic
studies of peri- and postmenopausal women who complain of sleep disturbance have
documented that over half of these women had sleep apnea or restless leg syndrome, neither
of which is easily attributed to hot flushes.164 Third, for this relationship to be tenable, one
would expect that reported hot flushes would occur prior to the onset of depression (i.e., as a
precipitant of depression). Recent epidemiologic evidence suggests, however, that hot flushes
and depression can also occur independently and are mutually dissociable phenomena.54,62,
63,165 Data from both the SWAN study54,165 and Freeman and colleagues57 demonstrate that
hot flushes and the perimenopause are independent risk factors for depression. Thus, both hot
flushes and perimenopause-related ovarian events may impart separate risks for developing
depression at midlife. Indeed, Joffe and colleagues151 identified a significant association
between hot flushes and depression in perimenopausal, but not postmenopausal, women. In
our prospective study, hot flushes were not uniformly present in all women and, when present,
did not necessarily precede the depression. Consistent with prior studies, eight of the nine
women experiencing depression reported the onset of hot flushes at some point during the
perimenopause,57,151 however, the timing of the relationship varied from several years before,
to several years after, the onset of depression. Only four (44%) of the women who developed
a depression during the perimenopause reported the onset of hot flushes closely preceding the
development of their depression. Fourth, a recent, clinic-based study of women with
perimenopausal depression found that the presence of hot flushes distinguished neither the
pattern of presenting symptoms (including the severity of sleep disturbance) nor the clinical
characteristics (i.e., past psychiatric history, plasma FSH levels, severity of depression) in these
women.67 Thus, hot flushes appear to be neither a necessary nor sufficient accompaniment of
depression during the perimenopause, and perimenopausal depression cannot be dismissed as
epiphenomenal to hot flushes. Finally, the effects of estrogen therapy on hot flushes and
depression are dissociable; as mentioned above, there are women with perimenopausal
depression without hot flushes whose depression responds to estrogen treatment.73 Further, as
shown by Soares and colleagues,74 in women successfully treated for depression and hot
flushes, estradiol withdrawal results in a return of hot flushes, but not necessarily depression.
Thus, while hot flushes, sleep disturbance, and depression frequently cluster together in women
during the menopause transition, a linear, causal relationship in which hot flush–induced
dysomnia leads to perimenopausal depression remains to be confirmed.
Life Events, Social Support, and Aging
Some, but not all, studies have suggested that both midlife and the perimenopause are
characterized by stressful life events and that perimenopausal depression may occur secondary
to an increased number of stressful events, including personal losses.166 These stressors include
the following: (1) alterations in family roles, (2) changing social support networks, (3)
interpersonal losses, and (4) the physical effects of aging. Nevertheless, a causal role for such
environmental factors has not been demonstrated. Midlife and, in particular, the perimenopause
are not universally characterized by stressful life changes such as children leaving the home,
one’s becoming a grandparent, loss of employment, divorce or widowhood, or the onset of
medical illness.167 Thus, it would be incorrect to assume that perimenopausal depression is a
natural accompaniment of the stress of either midlife or the perimenopause.
Stressful events have been reported in association with depressive symptoms at midlife,42,51,
168,171 as well as in women with major and minor depression during the perimenopause.62,
172 In the study by Schmidt and colleagues,172 however, women with perimenopausal
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depression did not report a greater number of exit events (i.e., personal losses) than
asymptomatic perimenopausal women. Indeed, exit events, if they do occur, are not necessarily
associated with negative mood symptoms in women at midlife.173 Thus, although stressful
events are an accompaniment of both midlife and perimenopausal depression, there is no
evidence to support the claim that depression at this time in a woman’s life is caused by the
“empty nest” syndrome.
Several factors such as genetic predisposition,174,175 self-efficacy,176 overall health, and social
support177 may differentially modify the negative impact of life events and may determine
whether negative events trigger the onset of depression. It is therefore possible that these
variables may mediate the effects of negative life events on mood, resulting in depression
among susceptible perimenopausal women. (It is important to note, however, that a woman’s
depressed state at the time of interview may color her perception of both the quantity and impact
of negative events in her recent past.)
Models describing the menopause as a life crisis misrepresent both the negative impact of this
developmental state and the universality of such an impact.42 The determinants of an
individual’s response to stressors, whether associated with the midlife or other developmental
stages, are likely multifactorial and complex. It remains unclear which factors determine
personal responses to crisis—whether they are positive, resulting in goal achievement, mastery,
and a feeling of satisfaction with one’s self and one’s contributions,167 or negative, resulting
in symptoms of emotional distress, low self-esteem, and depression.178
Summary
Perimenopausal depression is not simply the effect of abnormalities in ovarian steroid
production and is not merely secondary to severe hot flushes or personal losses. Nonetheless,
data suggest that each of these factors may play a role in perimenopausal depression and could
potentially cause depression in certain women. Many of these same factors are also present,
however, in the majority of perimenopausal women who do not develop depression. Thus, the
mediating or protective factors involved in the development of depression remain to be
determined.
CLOSING REMARKS
The relationship between the onset of depressive illness and reproductive aging has been a
source of controversy. The epidemiologic and clinic-based studies that have distinguished
between the perimenopause (a time of considerable variability in ovarian hormone secretion)
and the postmenopause (a time when hormonal changes have long since stabilized) suggest
that in some middle-aged women, the perimenopause is associated with an increased
vulnerability to depression. Additional support for this suggestion is provided by double-blind,
randomized, controlled trials documenting the therapeutic efficacy of estradiol in
perimenopausal depressed women but not in postmenopausal depressed women. Our future
efforts should abandon the all-or-none controversy and should be directed toward
understanding the determinants and consequences of the variability that we see in the
following: the response to change in reproductive endocrine function; the response, whether
therapeutic or adverse, to hormonal therapy; the impact and duration of hypogonadism; and
the behavioral effects of the large array of hormone receptor agonists and modulators.
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